V
Vinod Pullarkat
Researcher at City of Hope National Medical Center
Publications - 280
Citations - 9132
Vinod Pullarkat is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 37, co-authored 219 publications receiving 6536 citations. Previous affiliations of Vinod Pullarkat include University of Southern California & Biogen Idec.
Papers
More filters
Journal ArticleDOI
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)
Brian Ball,Shukaib Arslan,Paul Koller,Dat Ngo,Michelle Afkhami,Amandeep Salhotra,M. Monzr Al-Malki,Ahmed Aribi,Haris Ali,Karamjeet S. Sandhu,Salman Otoukesh,I. Amanam,Hoda Pourhassan,Andrew S. Artz,Peter T. Curtin,Anthony S. Stein,Ryotaro Nakamura,Guido Marcucci,Eileen P. Smith,Vinod Pullarkat,Ibrahim Aldoss +20 more
TL;DR: Rearrangements of lysine this article were used in this article for the extraction of Lysine-Lysine pairs from the lysines of proteins, and
Journal ArticleDOI
Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL
Karamjeet S. Sandhu,Alan Macias,Marissa Morales Del Real,Asuscena L. Beltran,Young Sun Kim,Jianying Zhang,Joycelynne Palmer,Marjorie Robbins,Reyna Loomis,Mojtaba Akhtari,Ahmed Aribi,Shukaib Arslan,Amandeep Salhotra,Matthew Mei,Hoda Pourhassan,Paul Koller,I. Amanam,Vaibhav Agrawal,Peter T. Curtin,Ricardo Spielberger,Vinod Pullarkat,Ibrahim Aldoss,F. Stewart,Eileen P. Smith,Stephen J. Forman,Anthony S. Stein,Guido Marcucci,Lihua E. Budde +27 more
TL;DR: In this article , the combination of pembrolizumab and blinatumomab in a single arm, phase 1/2 trial (NCT03512405), was evaluated.
Journal ArticleDOI
Poster: AML-491 Real World Practice of FLAG-Idarubicin-Venetoclax in Relapsed Refractory AML: A Single Center Experience
Brian Lee,Amanda L. Blackmon,Dat Ngo,Jason Y. Chen,Haoyue Shan,Amrita J. Desai,Andrew S. Artz,Ibrahim Aldoss,Monzr M. Al Malki,Amandeep Salhotra,Brian Ball,Paul Koller,Vinod Pullarkat,Ryotaro Nakamura,Anthony S. Stein,Guido Marcucci,Karamjeet S. Sandhu +16 more
Journal ArticleDOI
P515: lower-intensity cpx-351 + venetoclax for patients with newly diagnosed acute myeloid leukemia who are unfit for intensive chemotherapy
G. Uy,Vinod Pullarkat,Praneeth Baratam,Robert K. Stuart,Roland B. Walter,Eric P. Winer,Stefan Faderl,V. Chandrasekaran,Q. Wang,Divya Chakravarthy,Ronald S. Cheung,Tara L. Lin +11 more
TL;DR: In this article , the authors evaluated the safety and efficacy of lower-intensity CPX-351 + VEN in adults with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy (IC).
Journal ArticleDOI
Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
Tanya Markary,Tina Nguyen,Ni-Chun Tsai,Shukaib Arslan,Salman Otoukesh,I. Amanam,Brian Ball,Paul Koller,Hoda Pourhassan,Vaibhav Agrawal,Len Farol,Karamjeet S. Sandhu,Andrew S. Artz,Amandeep Salhotra,Ibrahim Aldoss,Vinod Pullarkat,Haris Ali,Peter T. Curtin,Anthony S. Stein,Guido Marcucci,Stephen J. Forman,Ryotaro Nakamura,Monzr M. Al Malki +22 more
TL;DR: In this article , the authors evaluated the impact of renal dysfunction on melphalan-based RIC HCT outcomes and regimen-related toxicities and morbidities in patients aged 55-75 years old.